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Background: Experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, is induced
by immunization of mice with myelin oligodendrocytic glycoprotein (MOG35-55) injections, and after 9 days, mice
develop behavioral signs of chronic progressive EAE. Proliferation of T and B cells located in peripheral lymph
tissues such as spleen and inguinal lymph nodes of C57BL/6J mice are stimulated. The opioid growth factor-opioid
growth factor receptor (OGF-OGFr) axis has been shown to effectively limit progression of chronic EAE when mice
are treated at the time of induction or at time of established disease. In addition to repressed behavioral profiles,
spinal cord neuropathology is diminished in mice treated with OGF or low dosages of naltrexone (LDN). However,
there is little or no information on peripheral lymphocyte dynamics following immunization of mice with MOG
antigen and treatment with OGF or LDN.
Methods: Six-week old female mice were immunized with MOG35-55 and were injected intraperitoneally with
OGF or a low dosage of naltrexone (LDN) beginning at the time of immunization; saline-injected immunized mice
served as controls. Normal mice received saline for all injections. Periodically over a 2 week period, spleens and
inguinal lymph nodes were removed, total lymphocytes counted, and subpopulations of CD4+ and CD8+ specific
T-cells, as well as B lymphocytes, were determined by flow cytometry. On day 15 of treatment, lumbar spinal cord
tissue was removed; CNS lymphocytes isolated, and assayed for Th1, Th2, and Th17 markers by flow cytometry.
Results: Exogenous OGF or endogenous OGF following LDN suppressed T and B lymphocyte proliferation in the
spleen and inguinal lymph nodes of MOG-immunized mice. Suppression of peripheral immune cell CD4+ and
CD8+ T cell proliferation at 5 and 12 days correlated with reductions in clinical behavior. EAE mice treated with
OGF for 15 days displayed elevated Th1 and Th17 cells; no subpopulations of Th2-specific T cells were noted.
Conclusions: OGF or LDN repress proliferation of CD4+ and CD8+T cells and B220+ B lymphocytes in the spleen
and lymph nodes of immunized mice within a week of immunization. These data provide novel mechanistic
pathways underlying the efficacy of OGF and LDN therapy for MS.
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Peripheral T and B cell proliferation represents a
hallmark of immune response to an antigen. In
autoimmune disorders such as multiple sclerosis
(MS), the self-antigen is unknown. The animal model
of MS, experimental autoimmune encephalomyelitis
(EAE), results from injection of small fragments of
proteins associated with myelin such as myelin oligo-
dendrocytic glycoprotein (MOG35–55) or polylipo-
protein (PLP139–155)[1,2]. MOG35–55 immunization
causes a chronic progressive form of EAE in C57Bl/6
mice, whereas PLP induces a relapse-remitting form
of EAE in SJL mice [3-5]. Initial phases of develop-
ment of both diseases are reliant on proliferation of
T and B lymphocytes. The pathophysiology of both
EAE and MS involves proliferation of CD4+ and
CD8+ T lymphocytes, followed by CD4+ T cell-
mediated demyelination [5,6]. Further proliferation of
B cells and other T-cell subsets derived from secondary
lymphoid tissues provide the basis for the inflamma-
tory responses associated with EAE/MS [5-19].
Many of the FDA approved therapies for MS target
CD4+ T cell signaling pathways, conversion of CD4+ T
cells to T helper cells (Th1 and Th2), and transition of
Th1- cells to Th17-T cells [4,10,11]. However, many of
the disease-modifying therapies that target T cell prolif-
eration are not completely successful, and new
immune-cell mediated treatments have utilized B cell
replication, as well as redistribution of T cell sub-
populations, for their approach to stabilizing disease
[8,10]. In response to immunization, antigen presenting
cells such as dendritic cells secrete a variety of cyto-
kines that stimulate CD4+ T cells to become differenti-
ated into Th1, Th2, or Th17 through a process known
as polarization [5]. Th1 cells are often considered pro-
inflammatory, respond to IL-12, and produce IFN-γ,
which enhances the pathway of CD4+ T cell prolifera-
tion and inflammation [5,15,16]. Th2 cells are con-
sidered to be anti-inflammatory because of the
specific cytokines associated with them, including IL-4
shown to decrease disease severity. IFN-γ is known to
inhibit Th2 polarization and thus exacerbate immune-
responses to EAE [17]. Preproenkephalin mRNA has been
detected, along with neuropeptides leucine enkephalin
and methionine enkephalin (also termed OGF) in CD4+
Th1 and Th2 lymphocyte subpopulations [18]. However,
the enkephalin prohormone was not required for Th1
differentiation. Transition of Th1 cells to the Th17 sub-
population, or increased Th17 subpopulations, are consid-
ered part of a “repair” mechanism and response of EAE
pathogenesis [19].
The opioid growth factor (OGF) – OGF receptor
(OGFr) pathway is a regulatory pathway involved in
homeostatic cell replication. The OGF-OGFr pathwayhas been implicated to regulate immune-activated cell
proliferation in a number of diseases including MS and
animal models of EAE [20-26]. OGF, chemically termed
[Met5]-enkephalin, is an inhibitory growth factor that
binds to OGFr in a selective manner to upregulate
cyclin-dependent inhibitory kinases and thus suppress
replication. Low doses of naltrexone (LDN) work by
biofeedback mechanisms to stimulate endogenous pep-
tide and receptor release, thus providing enhanced
inhibitory action. OGF and LDN therapies have been
examined in both chronic progressive and relapse-
remitting models of mouse EAE [20-26]. Systemic in-
jections of OGF or LDN initiated at the time of disease
induction by MOG35–55 demonstrated markedly less
severe clinical signs of disease and reduced spinal cord
neuropathology in C57Bl/6 J mice [20-22]. OGF treat-
ment initiated at the time of established progressive
disease reversed the course of EAE within 6 days [23].
Evaluation of spinal cord tissues demonstrated reduced
numbers of activated astrocytes, microglia/macro-
phages, and damaged neurons, as well as decreased
demyelination [23]. OGF and LDN therapy of established
relapse-remitting EAE whereby PLP139–151 is injected into
SJL/J mice and after 2 consecutive days of clinical signs
of disease, mice are injected with OGF or LDN, re-
vealed diminished peak disease scores for both treat-
ments, and a significant number of mice experiencing
partial, if not complete, remissions [24-26]. These data
support the role of endogenous opioid suppression of
EAE progression.
Previous work has shown that T and B lymphocytes
isolated from normal mice, and stimulated in culture to
divide, had significantly reduced proliferation following
administration of OGF or LDN [27,28]. OGF inhibited
lymphocyte cell replication in a dose-dependent, revers-
ible and receptor mediated manner. Reduction of OGFr
by siRNA technology prevented OGF’s inhibitory action.
Moreover, no other exogenous and endogenous opioid
peptides had an effect on inhibiting T or B cell replica-
tion in culture [27,28]. These in vitro data, along with
the behavioral consequences of OGF or LDN on EAE
mice, support the role of the OGF-OGFr axis as an
important regulation pathway in early phases of EAE.
In adaptive immune diseases such as EAE, T cell ex-
pansion occurs in a dynamic manner which influences
expression of clinical disease and response to immuno-
therapy [29-34]. The present experiments investigate
how OGF or LDN alter early phases of immune re-
sponse in EAE, and study whether endogenous opioids
such as OGF selectively inhibit the proliferation of one
or more subpopulations of T lymphocytes. These studies
provide an improved understanding of mechanistic
pathways involved in repression of MS by LDN or OGF
therapy.
Figure 1 Behavior of mice immunized with myelin oligodendrocytic protein (MOG) to induce EAE and treated with OGF or LDN. Behavioral
scores of mice immunized with MOG33–55 and treated daily with either 10 mg/kg OGF (OGF) or 0.1 mg/kg naltrexone (LDN); control mice
received intraperitoneal injections of 0.1 ml saline (saline). Mice were evaluated daily and scored (0–10 scale) by multiple observers, with one
masked to treatment. Values represent means ± SEM; N = 5 or 6 mice/group. Significantly different from saline-injected mice at p < 0.05 (*).
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Behavioral profile
Mice immunized with MOG35–55 were observed daily
and behavior scored by an observer masked to the
identity of the mouse. Clinical disease appeared on day 9
or 10 for all mice (Figure 1). By day 11, mice receiving
OGF or LDN beginning at the time of disease induction
had significantly reduced behavioral scores, with an
average of 0.5 or less for both groups in comparison to
saline-treated mice with mean scores of 1.5 and 2 on
days 11 and 12, respectively. By day 15, saline-treated
EAE mice had behavioral scores of 3 indicating some
paralysis, whereas mice in the OGF group had a mean
disease score of 1.5. The reductions in overall disease
scores were less that those reported for larger groups of
mice [22].Total lymphocyte number in non-immunized, normal
mice
The average numbers of lymphocytes isolated from the
spleens of control, non-immunized C57Bl/6 mice on
days 5, 12, and 15 were 4.9 x 107, 5.8 x 107 and 6.2 x
107, respectively. On day 5, the average number of
lymphocytes recorded in the inguinal lymph nodes of
normal, non-challenged mice was 4.1 x 105 (a 2.5 fold
increase in MOG-stimulated mice). On days 12 and 15,the average number of lymphocytes in normal inguinal
nodes ranged between 3.4 x 105 and 4.1 x 105.
Total lymphocyte number in spleens of MOG-immunized
mice
Splenic lymphocytes were isolated from non-immunized
and MOG-immunized mice (EAE) on days 5, 12, and 15,
and total cell number was recorded by a hemacytometer
(Figure 2). Five days following immunization, normal
C57BL/6 mice had approximately 76 million lympho-
cytes in the spleen in comparison to an average of 101
million lymphocytes in MOG-EAE mice (Figure 2). By
day 12, MOG-immunized mice had enlarged spleens
with 147 million lymphocytes in comparison to 58
million in non-immunized mice (p < 0.001). On day 15,
lymphocyte number increased to 181 million in the im-
munized mice and 70 million in the non-challenged
animals.
MOG-immunized mice received OGF or LDN begin-
ning at the time of immunization and continued daily
for 15 days (Figure 2). Within 5 days of treatment, both
OGF- and LDN-treatment reduced the total number of
lymphocytes in comparison to MOG-immunized mice;
MOG +OGF mice had 71 million cells, and MOG +
LDN animals had 75 million splenocytes, in comparison
to approximately 101 million cells in MOG + Saline
mice. On day 12, total lymphocyte number was
Figure 2 Effects of OGF or LDN on splenic lymphocytes from EAE mice. Lymphocytes isolated from spleens of C57BL/6 mice immunized with
MOG35–55 and injected daily with 10 mg/kg OGF (OGF), 0.1 mg/kg naltrexone (LDN) or 0.1 ml saline (saline); normal mice received saline at each
injection point. Splenocytes from 3–4 mice per treatment at 5 and 8 days were isolated, labeled, and sorted by flow cytometry. Values represent
means ± SEM. Significantly different from normal mice at p < 0.05 (*) or p < 0.001 (***), and from saline-treated immunized mice at p < 0.05 (+) or
p < 0.01 (++).
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immunized mice receiving either OGF or LDN; treated
mice had approximately 97 million splenocytes in com-
parison to 147 million counted in MOG + Saline ani-
mals. On day 15, all groups of immunized mice had
between 131 and 181 million total lymphocytes in the
spleen.Subpopulations of splenic lymphocytes in OGF- and
LDN-treated MOG-immunized mice
Flow cytometric analyses of CD4+ and CD8+ T cells,
as well as B lymphocytes in the spleens of immunized
mice revealed that OGF and LDN reduced immune-
stimulated T cell proliferation at 5 and 12 days following
MOG immunization (Figure 2). B cell number was
inhibited by OGF and LDN on day 12.Within 5 days of treatment with exogenous OGF or
LDN, CD8+ T lymphocyte subpopulations in MOG +
OGF and MOG + LDN mice were reduced by 29% to
32% from that recorded for MOG immunized saline-
treated mice (Figure 2). CD4+ T cells in MOG +OGF or
MOG + LDN groups were reduced by approximately
30% from that of MOG + Saline mice. B cell number was
comparable for all groups of immunized mice and non-
stimulated animals.
After 12 days of treatment, MOG-immunized mice
receiving saline had approximately 18 million CD4+
splenic T lymphocytes, a 41% increase over non-
immunized animals (Figure 2). Animals receiving OGF
or LDN had 32-37% reductions in the number of CD4+
T cells relative to the number recorded for MOG +
Saline mice. The subpopulation of CD8+ T cells in the
spleens of MOG +OGF and MOG + LDN mice were
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as reduced relative to normal mice. B cell number was
elevated to 62 million, a 2-fold increase in comparison
to the 30 million B-cells recorded in non-immunized
normal mice. OGF and LDN treatment markedly re-
duced the number of CD45 stained B220+ B cells by
approximately 29% from the saline-injected MOG
mice.
On day 15 following immunization and treatment,
OGF or LDN treatment had no effect on subpopula-
tions of T cells isolated from the spleen; CD4+ and
CD8+ T cell number ranged between 10 and 21 mil-
lion for all treatment groups, including normal mice.
B cell number in the spleen was elevated to 77 million
in immunized mice from 38 million recorded for nor-
mal animals. OGF and LDN treated groups had ap-
proximately 60 million B cells in the spleen.Figure 3 Inhibition of proliferation of T lymphocyte subpopulations in righ
Total lymphocytes isolated from right inguinal nodes of mice immunized wit
naltrexone (LDN), or 0.1 ml saline (saline); normal mice received saline at each
lymphocytes from 3–4 mice per treatment at 5 and 12 days were isolated, lab
Significantly different from normal mice at p < 0.05 (*), p < 0.01 (**), and p < 0.Right inguinal lymph node lymphocyte proliferation
Mice were initially inoculated with MOG35–55 on the
right side rendering the right inguinal node as a “drain-
ing node” on day 5. In comparison to 850,000 lympho-
cytes in a normal lymph node, stimulated mice had 6.6
million within 5 days of immunization (Figure 3). The
total number of lymphocytes in the right, draining in-
guinal node of MOG immunized mice reached 11 mil-
lion on day 15 in comparison to 1.2 million in normal
mice. OGF-treated mice had total lymphocyte counts
ranging from 4.8 to 11.4 Million, whereas LDN-treated
MOG-immunized mice had total cell numbers in the
right inguinal node of 4.6 to 12.6 million (Figure 3).
OGF and LDN treatment did not reduce the overall cell
number in the right inguinal node.
Analyses of T and B cell subpopulations using flow
cytometry demonstrated that MOG-immunizationt inguinal nodes in EAE mice following OGF or LDN treatment.
h MOG35–55 and injected daily with 10 mg/kg OGF (OGF), 0.1 mg/kg
injection point. Right nodes were activated following injections on day 0;
eled, and sorted by flow cytometry. Values represent means ± SEM.
001 (***), and from saline-treated immunized mice at p < 0.05 (+).
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6-fold over normal mice, while B220+ cells detected by
CD45 antibody were increased 15-fold in the right
inguinal node within 5 days of injection of MOG
(Figure 3). OGF and LDN treatment reduced CD4+ T
cell number in the right inguinal node of MOG mice by
35 and 41%, respectively, on day 5. Although CD8+ and
CD45+ specific T and B cells, respectively, were re-
duced by OGF and LDN, values were not significantly
different.
After 12 days of immunization, and 7 days after direct
injection near the right inguinal node, the right inguinal
node of MOG + Saline mice had 4.5-fold more CD4+ T
cells than recorded in nodes of non-stimulated animals.
OGF or LDN treatment did not alter CD4+ subpopula-
tions of lymph nodes cells. However, OGF reduced CD8
+ T cells in the right lymph node by 43%, and LDN
reduced cell number by 10%, in comparison to values
reported for MOG + Saline mice. The subpopulation of
B220+ B cells, as detected by CD45 antibodies, was in-
creased 9- to 14- fold in the immunized groups relative
to non-stimulated mice. Although OGF reduced B cell
subpopulations in the right lymph node by 33%, values
did not differ significantly from the MOG + Saline group;
LDN treatment did not alter CD8+ T cell or B cell
subpopulations.Figure 4 Inhibition of proliferation of T lymphocyte subpopulations in left
lymphocytes isolated from the left inguinal nodes of mice immunized with
naltrexone (LDN), or 0.1 ml saline (saline); normal mice received saline at ea
on day 12, 5 days following injection on the left flank. Lymphocytes from 3
sorted by flow cytometry. Values represent means ± SEM. Significantly diffe
and from saline-treated immunized mice at p < 0.05 (+).Approximately 2 weeks after immunization (day 15),
the total number of lymphocytes in the right inguinal
node of immunized mice was approximately 5-fold
that of non-stimulated animals, and comparable
among all groups of MOG35–55 inoculated mice.
Subpopulations of T cells were elevated approximately
5-fold and 6-fold respectively for CD4+ and CD8+ T
cells, and more than 17-fold for CD45 positive B cells.
OGF and LDN did not alter the subpopulation distri-
bution in the right inguinal node at this time.
Left inguinal lymph node lymphocyte proliferation
The second inoculation of MOG35–55 was on the left
side on day 7 which stimulated the left inguinal node
to become activated by day 12. Thus, on day 5, the
total number of lymphocytes in the left inguinal node
was comparable between all treatment groups, and
ranged between 500,000 to 1.5 million cells (Figure 4).
Subpopulations of T and B lymphocytes ranged from
100,000 to 500,000 cells. Nonetheless, OGF treatment
inhibited cell replication of the CD4+ T cells by 64%;
with only 185,000 cells recorded from MOG + OGF
mice in comparison to 516,000 cells in the MOG +
Saline animals. LDN reduced CD4+ T cells by 69% in
comparison to MOG + Saline cell numbers. Although
CD8+ T cells were reduced more than 50% by bothinguinal nodes in EAE mice following OGF or LDN treatment. Total
MOG35–55 and injected daily with 10 mg/kg OGF (OGF), 0.1 mg/kg
ch injection point. The left inguinal node was considered “draining”
–4 mice per treatment at 5 and 12 days were isolated, labeled, and
rent from normal mice at p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***),
McLaughlin et al. BMC Immunology  (2015) 16:24 Page 7 of 11OGF and LDN, values were not significantly different.
CD45 stained B220+ B cell number ranged between
143,000 and 479,000 cells on day 5.
On day 12, cell number in the left inguinal node
increased in the immunized mice to 5.1 – 6.1 million
total lymphocytes (Figure 4). Although immunization
significantly increased the number of CD4+ and CD8+
T cells, as well as CD45+ B cells, the number of lym-
phocytes in the left inguinal node was not inhibited by
OGF or LDN.
By day 15, total left inguinal node cell number in-
creased to greater than 10 million, in comparison to 1.2
million cells in the non-immunized mouse. Subpopula-
tions of CD4+ T cells increased to 2 million in MOG-
stimulated mice relative to less than 500,000 in the left
inguinal node of normal mice. Similar profiles for expan-
sion of CD8+ T cells were noted in the MOG-
immunized mice; LDN and OGF had no effect on cell
proliferation at 15 days.Intracellular distribution of CNS derived lymphocytes
CNS derived lymphocytes isolated from the lumbar
spinal cord of MOG-immunized mice treated for 15 days
with OGF, LDN, or saline were assessed by intracellular
cytokine staining. Cell homogenates were labeled with
markers for CD4+ T cells, as well as for cytokines that
were expressed on Th1, Th2, and Th17 subsets of T cells
(Figure 5A). From six spinal cords per group, 5.25x106,
4.35x106, and 2.85x106 lymphocytes were collected from
the saline, OGF, and LDN treated groups respectively.
Lymphocyte subpopulations were counted and revealed
that the number of CD4+ cells for saline, OGF, and
LDN groups were 1,645,175, 2,663,500, and 990,000 cells
respectively. IFN- (FITC-stained) cells totaled 1,291,850,
2,063,000, and 759,000 cells respectively for saline, OGF,
and LDN treated mice. Th2 (IL-4, APC stained) cells
numbered 855 for LDN treated mice and negligible/
none for saline and OGF treated mice. The largest
number of Th17 cells were recorded in OGF mice
(1,071,000) in comparison to 573,000 for saline-treated
mice, and 270,300 for LDN treated animals. Of the
lymphocytes analyzed by flow cytometry, OGF treatment
resulted in a 1.9-fold increase in the percentage of total
lymphocytes that were CD4+ T cells relative to the num-
ber recorded for saline-treated MOG-immunized mice
(Figure 5B, C). OGF treatment resulted in an increase in
the ratio of double- stained CD4+/IFN-γ (Th1) and CD4
+/IL-17 (Th17) cells in comparison to the number of
cells gated in the MOG + Saline group. OGF exposure
increased the percentage of Th1 and Th17 cell sub-
populations by 1.9-fold and 2.2-fold, respectively, as
compared to the saline group (Figure 5C). LDN treat-
ment did not alter the ratio of CD4+ T cells or thenumber of Th1, Th2, and Th17 subsets. Th2 cells, often
considered as “anti-inflammatory”, were not detected.
Discussion
Enkephalins have always been considered to have immu-
nomodulatory properties [30]. The role of T and B cell
proliferation in mice with experimental autoimmune
encephalomyelitis is of great interest, and many papers
have shown a biphasic proliferative role in cells, with
T cell proliferation increased early in the process of
immunization, and then reduced several weeks following
antigen stimulation [31-34].
The present study is the first to demonstrate the
inhibitory effect of the endogenous opioid OGF on cell
proliferation, and particularly on inhibition of T cell
proliferation in vivo. Previous work in our laboratory re-
vealed that in vitro stimulation of T cells by phytohem-
agglutinin and incubation with OGF diminished cell
replication. Splenic cells isolated from normal mice and
treated with 10 μg phytohemagglutin per ml of media
were stimulated to proliferate; treatment with OGF re-
duced cell proliferation in a dose-dependent manner.
The repressive effects of OGF on proliferation were
mediated through OGFr, as reduction of OGFr protein
by siRNA technology removed the inhibitory effect of
OGF [35]. The present experiments expand on our
in vitro data [27,28] that demonstrated the presence of
both OGF and OGFr in lymphocytes, and demonstrate
that in vivo manipulation of the OGF-OGFr axis alters
proliferation of different subpopulations of T and B lym-
phocytes in peripheral lymph tissue and spinal cord. Our
tissue culture studies on T and B cell proliferation reveal
that the mechanism of OGF’s inhibitory activity on cell
number is by reducing DNA synthesis, and not by
enhancing apoptosis or necrosis [27,28]. Incorporation of
tritiated thymidine into the splenocytes in cultures also
demonstrated the inhibitory effect of OGF. Treatment of
stimulated T and B cells with other opioid agonists such
as leucine enkephalin, endomorphin 1, β-endorphin,
dynorphin 1–13, or morphine had no effect on immune
cell-specific proliferation. In fact, β-endorphin may en-
hance cell proliferation of immune cells through non-
opioid receptor mechanisms [31].
Reports on whether opioid peptides alter T and B cell
proliferation are often conflicting [36-38]. Differences in
the studies as to whether opioids inhibit or enhance
immune-cell replication in vitro depend of a number of
experimental factors including variations in dosage, class
of peptide (natural or synthetic), whether cells are
stimulated or not, and length of treatment. OGF did not
affect proliferation in unstimulated cells in culture, or
splenic cells in vivo.
Most studies on T and B cell proliferation in mice with
an autoimmune disease are focused on conversion of
Figure 5 Differential T cell subpopulations in spinal cord of EAE mice treated with OGF or LDN. Differential cell counts of lymphocytes isolated
from spinal cords isolated from mice immunized with MOG35–55 and treated from the time of induction with 10 mg/kg OGF (OGF), 0.1 mg/kg
naltrexone (LDN), or 0.1 ml saline (saline); normal mice received saline at each injection point. Representative FACS profiles of T-cell populations
obtained by fluorescence-activated cell sorting. Lymphocytes were isolated from spinal cord and stained with markers for CD4+, Th1, Th2, and
Th17T cells. (A) Parameters for representative flow cytometry dot plots. (B) Representative flow cytometry dot plots for OGF, LDN, and saline
treated mice 15 days after immunization with MOG35–55. (C) Histograms represent the percentage (± SEM) of electronically gated cells obtained
from flow cytometry; samples were run in triplicate. Little or no Th2 cells were detected. Significantly different from saline-treated mice at
p > 0.001 (***).
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or Th17 [18,19]. In the present studies, mice challenged
with MOG35–55 peptide displayed clinical signs of
experimental autoimmune encephalomyelitis by day 11
or 12. Clinical signs of behavioral deficits were evident
on days 11 and 12 in the LDN group and on days 11–15
for the OGF-treated group. The behavioral scores in this
experiment were limited to a small number of mice in
comparison to other studies where mean disease scores
were 50 to 75% reduced in animals treated with OGF or
LDN relative to saline-treated EAE mice [22]. The min-
imal effects of LDN on behavior most probably extend
to T cell proliferation as well, suggesting that a more
robust effect is possible and that animal variation is
always evident in behavioral studies.
Day 15 appeared to be the peak day of proliferation
of splenic lymphocytes, whereas cell replication in
inguinal lymph nodes peaked on day 15. OGF and LDN
inhibited CD4+ and CD8+ T cell subpopulations, as
well as CD45 stained B cells relative to values from
saline-treated MOG-immunized mice on day 12. The
greatest effects of OGF and LDN treatment on inhibit-
ing the proliferation of T and B cell subpopulations in
lymph nodes occurred on day 5. Total lymphocyte
numbers were inhibited by as much as 40% following
only 5 injections of OGF in comparison to total im-
mune cell numbers in MOG immunized mice. Direct
injections of OGF, rather than endogenous OGF stimu-
lated by LDN, were more effective at repressing B and
T lymphocyte replication. LDN had minimal effect
inhibiting B cells in this model of EAE. With regards to
CNS derived lymphocytes, OGF stimulated Th1 cell
proliferation suggesting that cell-mediate immunity and
interferon-γ and interleukin (IL)-2 are upregulated. The
lack of Th2 cells being detected in the spinal cord may
reflect the course of disease and the early period of
sample collection (15 days) as Th2 cells tend to prolif-
erate to inhibit phagocytic-dependent inflammation.
The presence of Th17, but not Th2 cells, does not ne-
cessarily indicate that there are no anti-inflammatory
cells responding to the antigen presentation [39,40].
Th17 effector cells, along with Th1 cells, are polarized
to cause inflammation. Mice lacking either Th1 or
Th17 were not immunoprotected suggesting that nei-
ther subset alone is responsible for disease progression.
The increased proliferation of Th1 cells might simply
reflect the early stage of disease and the peak flair; the
lack of effect by OGF might indicate that treatment
with endogenous opioids shifts the timetable of disease
earlier so that Th1 cells are degrading intracellular
pathogens earlier in the process, moving forward with
anti-inflammatory response. Additional studies would
be required for a complete investigation of Th1 to
Th17 transition.Conclusion
The OGF-OGFr pathway regulates proliferation of per-
ipheral immune cells following stimulation by MOG35–55
antigen. Exogenous OGF or endogenous OGF following
LDN treatment inhibited CD4+ and CD8+ T and B cell
replication within the spleen and draining inguinal nodes
within the first week of immune-related response, and
in spinal cord tissue on day 15 following antigen
stimulation. These data support that modulation of the
OGF-OGFr pathway is an effective therapeutic para-
digm for MS.
Methods
Animals and induction of EAE
The mouse model of chronic EAE was established in
6-8-week old, female C57BL/6 J (stock 000664) mice,
purchased from Jackson Laboratories (Bar Harbor, ME).
Mice were housed, 5 per cage, in rooms maintained at
21 ± 0.5°C with a relative humidity of 50 ± 10%, with a
complete exchange of air 15–18 times per hour and a
12 hour light–dark cycle with no twilight. Food and
water were available ad libitum. All experiments were
conducted in accordance with National Institute of
Health guidelines on animal care and were approved by
the Penn State Hershey Institutional Animal Care and
Use Committee.
To induce chronic progressive EAE, each mouse
received 400 μg myelin oligodendrocyte glycoprotein
(MOG35–55) dissolved in 0.1 mL sterile phosphate buff-
ered saline (PBS); 750 μg mycobacterium tuberculosis
(H37RA, Difco Laboratories, Detroit, MI) was added to
0.15 mL incomplete Freund’s adjuvant (Sigma-Aldrich,
St. Louis, MO) to create complete Freund’s adjuvant
(CFA). Equal volumes of the PBS containing MOG35–55
and CFA were emulsified by vortexing. Mice were lightly
anesthetized and injected subcutaneously on the right
flank with 0.2 mL of the MOG35–55 emulsion (Peptides
International, Louisville, KY). A second injection of
MOG emulsion was injected in the left flank one week
later. In addition, animals received an intraperitoneal
injection of 500 ng pertussis toxin (List Biological
Laboratories, Campbell, CA) dissolved in 0.2 mL PBS on
days 0 and 2 of the study. Normal control mice were
anesthetized and received sterile PBS injections of equal
volume in place of MOG and pertussis immunizations.
Mice were lightly anesthetized with 3% isoflurane
(Vedco, Inc., St. Joseph, MO) for antigen and M. tuber-
culosis injections.
At the time of disease induction some mice were
randomized to receive daily intraperitoneal injections
(0.1 mL) of either 10 mg/kg OGF (Polypeptide Labora-
tories, Torrance, CA), 0.1 mg/kg naltrexone (LDN;
SigmaAldrich, Indianapolis, IN), or an equal volume of
sterile phosphate-buffered saline. All injections were
McLaughlin et al. BMC Immunology  (2015) 16:24 Page 10 of 11given between 9.00 and 10.00 hr; anesthesia was not
required for daily OGF or saline treatments. Animals
were weighed weekly in order to adjust drug dosages.Behavioral observations
Animals were observed daily to evaluate the onset and
progression of EAE [23]. Mice were placed individually
on a clean, flat surface and behavior scored by 2 ob-
servers, one masked to treatment. Disease severity was
evaluated on a 0 – 10 scale, with 0 representing no dis-
ease and 10 representing death due to EAE. Specifically,
observations of tail tonicity, gait, righting reflex and limb
function were scored and summed to provide a daily
disease score [23]. Righting reflex tests were performed
by placing the animal on its back and scoring the ability
to return quickly to all four limbs. Limb function was
scored by placing the mouse in an inverted position on a
grid and observations of normal, weak, near paralysis or
paralyzed limbs were assessed for each forelimb and
hindlimb [23]. Mice with both hindlimb and forelimb
paralysis received a score of 9, and death due to EAE
was scored as 10.Lymphocyte isolation
For studies on chronic EAE, mice (3–5 per treatment
group) were euthanized by cervical dislocation on days
5, 12, and 15 following immunization and lymphocytes
processed according to published procedures [41-43].
Spleens and lymph nodes (right and left were kept separ-
ate) were removed, dissociated using 60-mesh stainless
steel screens, and splenocytes or lymphocytes collected
from their respective tissues. Red blood cells were lysed
and cellular debris was removed by centrifugation.
Lymph nodes of normal, unimmunized mice were
pooled. Isolated lymphocytes were resuspended in
Iscove’s modified Dulbecco’s media supplemented with
0.075% fetal calf serum, sodium bicarbonate, and β-
mercaptoethanol, and counted using a hemacytometer
and trypan blue exclusion staining.Lymphocyte subpopulation proliferation
Lymphocytes were stained with anti-CD4-PE conjugated
antibody (clone GK1.5), anti-CD8a APC-conjugated
antibody (clone 53–6.7), and anti-CD45R-FITC conju-
gated antibody (Clone RA3-6B2) to detect CD4+, CD8+,
and B220 lymphocytes respectively; all reagents were
purchased from eBioscience [41-43]. Cells isolated from
spleen or right and left lymph nodes were stained, resus-
pended in FACS buffer, and analyzed by flow cytometry
on a Becton Dickinson FACScan flow cytometer. Cell
suspensions were processed in triplicate. Dot plots were an-
alyzed with FlowJo© software (TreeStar, Inc, Ashland, OR).Intracellular cytokine staining of CNS lymphocytes
On day 15, spinal cord tissue was extracted from eutha-
nized mice and pooled for each treatment group (N = 6).
Tissue was dissociated and lymphocytes collected at
the interface of a 63% - 27% Percoll gradient, plated in
Iscove’s Modified Dulbecco’s Medium (IMDM) and
stimulated overnight with phorbol 12-myristate 13-acetate
(20 nM and ionomycin (1 μM) in IMDM at 37°C.
Brefeldin-A was added at a final concentration of 9 μg/ml
and incubated for 6 hours. Fc receptors were blocked with
2.4 g2 Fc blocking reagent in 10% normal mouse serum,
followed by extracellular staining with anti-CD4+ anti-
body conjugated to PE. Cells were then washed, fixed, and
permeabilized (Fix & Perm kit, Invitrogen, Grand Island,
NY) and stained with antibodies to Th1, Th2, and Th17
using FITC conjugated anti-IFN- γ, APC conjugated anti-
IL-2, and PerCP Cy5.5 conjugated anti-IL-17, respectively
(eBioscience, San Diego, CA) following modifications
of published and manufacturer’s instructions [5,6,43].
Replicate samples of stained cells were processed in
the Core Faculty using a FACSCalibur flow cytometer
(BD Bioscience).Statistical analyses
Tissues from 2 or 3 mice per treatment group at each
time were collected; flow cytometry runs were made in-
dependently for 2 separate experiments. Experiments
were performed in duplicate or triplicate; 50,000 events
were collected per run. All data and plots from the flow
cytometer were analyzed using CellQuest Pre software.
Numerical data were analyzed by GraphPad Prism
(GraphPad Prism Software, La Jolla, CA) using one-way
analysis of variance with subsequent comparisons made
using Newman-Keuls tests.
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